Faraz Ali has been appointed CEO of preclinical-stage biotechnology company, Tenaya Therapeutics.
The California-headquartered firm is focused on the discovery and development of novel therapies for heart failure.
“The Board felt his strategic vision, track record of relevant operational experience, and commitment to building a leading heart failure company over the long-term make him an outstanding choice for Tenaya,” said chairman of the board of directors, David Goeddel.
Outgoing CEO JJ Kang agreed with Goeddel, "Faraz's previous experiences with novel therapies for rare diseases as well as for larger indications will be a great asset to Tenaya as the company evaluates and advances its research pipeline towards the clinic. The breadth of his business experiences is an excellent complement to the deep scientific expertise at Tenaya."
Prior to working at Tenaya, Ali served as chief business officer at Regenxbio, vice president at Bluebird Bio, and held roles at Genzyme Corporation and GE Healthcare.
Ali is a graduate of Harvard Business School and Stanford University.